CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …

Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Introduction Current evidence indicates that rivaroxaban may be a safe and effective
alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity …

Atrial fibrillation (AF) and coronary artery disease (CAD) often coexist. Both conditions confer
an increased risk of acute thrombotic complications. However, the pathogenesis of thrombus …

In addition to platelet aggregation, coagulation activation is considered to be involved in
arterial thrombosis. In this study, we determined antithrombotic effects of edoxaban, an oral …

Introduction: The number of atrial fibrillation (AF) patients requiring thrombo-prophylaxis with
oral anticoagulation is greatly increasing. The introduction of non-vitamin K oral …

Stroke prevention is the main priority in the management cascade of atrial fibrillation. Most
patients require long-term oral anticoagulation (OAC) and may require percutaneous …

Aim: Evaluate healthcare resource utilization (HRU) and costs associated with rivaroxaban
and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and …

Aim To assess the real-world healthcare resource utilization (HRU) and costs of patients
with non-valvular atrial fibrillation (NVAF) and obesity newly initiated on rivaroxaban or …